Top PBM to put Humira biosimilars on level playing field with AbbVie blockbuster
Humira is the best selling drug of all time. And as biosimilars for the drug venture onto the open market in Jan. 2023, one of the big three PBMs is making room for the biosimilars to compete on equal footing with the brand-name version.
UnitedHealth Group’s PBM OptumRx — one of the largest in the US along with CVS Health and Express Scripts — signaled Tuesday that it will place three biosimilars for the AbbVie-made drug sales king on its formulary, its preferred list of drugs, at parity with Humira, allowing biosimilars to compete on the same tier as the drug itself.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.